REPORT HIGHLIGHT

Thalassemia market was valued at USD 2.48 billion by 2019, growing with 9.7% CAGR during the forecast period, 2020-2026.

Thalassemia is an inherited or genetic blood disorder, which is characterized by the abnormal production of hemoglobin present in the blood cells of the human body. Hemoglobin is the protein that functions to carry oxygen all through the human body, which results in the annihilation of the blood cells leading to anemia.

Market Dynamics

The increasing population, growing demand for enhanced curative gene therapies, and rising awareness regarding available treatment options are the major factors boosting the growth of the global thalassemia market. According to the World Health Organization (WHO), approximately 4.4 every 10,000 live births are affected by thalassemia all across the globe. And, about 5% of the total world population has a variation in the beta or alpha part of the hemoglobin molecule. Furthermore, a surge in the development of pipeline drugs and novel therapies coupled with research & development is another factor propelling the market growth. However, high costs and the lack of viable treatment options associated with the disease are predicted to restrict the market growth in the coming future. On the contrary, the growing investments in healthcare by governments and various key players are expected to create lucrative growth opportunities in the overall market during the forecast period.

Thalassemia Type Takeaway

“Alpha thalassemia segment to witness the fastest growth during the forecast period”

Based on the thalassemia type, the global market is bifurcated into alpha-thalassemia and beta-thalassemia. Of these, the alpha thalassemia segment is estimated to grow at the fastest rate during the forecast period mainly because it is one of the most common autosomal disorders. The growing prevalence of alpha-globin disorders in the U.S. and other western countries is impelling the segmental market growth. In addition, the prevalence of alpha thalassemia is more as compared to the beta-thalassemia, which will fuel the growth of the alpha-thalassemia segment during the forecast period. On the other hand, the beta-thalassemia segment is projected to witness significant growth during the period of forecast. According to the WHO, around 1.5% of the worldwide population is affected by beta-thalassemia.

Therapeutic Class Takeaway

“Blood transfusion segment is anticipated to dominate the industry by 2026”

On the basis of therapeutic class, the overall market for thalassemia is categorized into iron chelating drugs, blood transfusion, folic acid supplements, and gene therapy. The iron-chelating drugs and the gene therapy segment are further sub-categorized into exjade/jadenu (deferasirox) and lentiglobin respectively. Among these, the blood transfusion segment accounted for the largest market share in 2019 and is expected to dominate the industry during the forecast period. This dominance is majorly attributed to the low risk involved in blood transfusion treatment due to careful blood screening. In addition, this treatment has a high success rate compared to other treatments, which makes it most preferable by patients. This will contribute to the segmental market growth in the projected timeframe.

On the other hand, the gene therapy segment is estimated to grow at a considerable rate during the forecast period as it has the potential to change the thalassemia treatment landscape amidst regulatory uncertainties and major clinical development challenges. In addition, scientists are involved in investigating several genetic techniques for the treatment of thalassemia.

Pipeline Products Takeaway

Gene therapy is considered to be the forefront of emerging curative therapies for thalassemia condition, with several genomic molecules under late stage clinical studies. Some of the key players’ have already initiative phase III trials for this condition while many are in preclinical evaluation. Recently, a new approach of gene editing for the correction of beta-globin mutation or disruption of the BCL11A gene has been initiated to increase fetal hemoglobin production. This molecule is expected to achieve the preclinical stage soon.

Furthermore, gene correction of autologous hematopoietic stem cells using Lentiviral vectors has been successfully established with a projected launch in the market by 2022. Even though curative possibilities for this disease is expanding, making it accessible to a larger number of patients on a global level remains a challenge.

End Use Takeaway

“Hospital segment to be most lucrative in the forecast period”

Based on end-use, the worldwide thalassemia market is classified into a hospital, research institute, laboratories, and clinics. Among these, the hospital segment accounted for the majority of share in the market in 2009 and is projected to lead the market during the forecast period. This is primarily owing to growth in the number of admissions in hospitals for thalassemia treatment. In addition, the growing prevalence of thalassemia is also likely to drive the segmental market growth. On the other hand, the laboratories segment is expected to hold a significant share in the market throughout the forecast owing to growing awareness amongst people regarding thalassemia treatment.

Regional Takeaway

“North America region to hold a significant market share by 2026”

Depending on the region, the global industry is divided into North America, Europe, Latin America, Asia Pacific, and Middle East & Africa. The North America thalassemia market held the highest market share in 2019 and is expected to grow at a significant rate during the period of forecast. This is majorly owing to increasing awareness of thalassemia and the rising incidence of alpha thalassemia in this region.

Moreover, the increased effort by the government in various countries of the North America region to support gene therapy is another responsible for the regional market growth. On the other hand, the Asia Pacific market for thalassemia is expected to grow at the fastest CAGR owing to increasing investments by governments in healthcare infrastructure.

COVID-19 Impact

The worldwide spread of COVID-19 disease has adversely affected the global thalassemia market. Multiple challenges are being faced by the market such as unavailability of blood in blood banks, transfusion facilities, and transportation for the treatment of thalassemia disorders. Moreover, the overall market is likely to recover at a slow rate post the COVID-19 pandemic.

Key Vendor Takeaway

The leading players of the global thalassemia market include Bluebird Bio, ApoPharmaInc, Sangamo Bioscience, Bellicum Pharmaceuticals, Pfizer, Inc., AcceleronPharma / Celgene Corporation, Novartis, KiadisPharma. These players are involved in R&D activities to develop an improved treatment for thalassemia to hold a strong position in the global industry. Companies are involved in developing new products for the disease treatment. For instance, recently, in January 2020, Bluebird Bio launched its first beta thalassemia gene therapy namely, ‘Zynteglo’ in Germany. A German manufacturer, apceth Biopharma is recruited by the company to produce Zynteglo.

The market size and forecast for each segment and sub-segments has been considered as below:

Historical Year – 2015 to2018
Base Year – 2019
Estimated Year – 2020
Projected Year – 2026
TARGET AUDIENCE

Traders, Distributors, and Suppliers
Manufacturers
Government and Regional Agencies
Research Organizations
Consultants
Distributors
SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLBOAL THALASSEMIA MARKET KEY PLAYERS

AcceleronPharma / Celgene Corporation
Novartis AG
Bluebird Bio
ApoPharmaInc
Sangamo Bioscience
Bellicum Pharmaceuticals
Pfizer, Inc.
KiadisPharma
GLBOAL THALASSEMIA MARKET, BY THALASSEMIA TYPE

Alpha Thalassemia
Beta Thalassemia
GLBOAL THALASSEMIA MARKET, BY THERAPEUTIC CLASS

Gene Therapy
LentiGlobin
Iron Chelating Drugs
Exjade/Jadenu (deferasirox)
Blood Transfusions
Folic Acid Supplements
GLBOAL THALASSEMIA MARKET, BY END-USE

Research Institutes
Hospital
Laboratories
Clinics
Others
GLOBAL THALASSEMIA MARKET, BY REGION

North America
The U.S.
Canada
Europe
Germany
France
Italy
Spain
United Kingdom
Rest of Europe
Asia Pacific
India
China
South Korea
Japan
Singapore
Rest of APAC
Latin America
Brazil
Mexico
Argentina
Rest of LATAM
Middle East and Africa
Saudi Arabia
United Arab Emirates
Rest of MEA